New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
11:37 EDTCYTK, NSR, NOW, ETFC, LFOptions with increasing implied volatility: CYTK NSR NOW ETFC LF
News For CYTK;NSR;NOW;ETFC;LF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
18:34 EDTNOWOn The Fly: After Hours Movers
UP AFTER EARNINGS: Select Comfort (SCSS), up 13.1% after reporting third quarter results and increasing share repurchase authorization to $250M... Infinera (INFN), up 9.8%... Tractor Supply (TSCO), up 11.8%... Acacia Research (ACTG), up 7.7%... Marketo (MKTO), up 4.5%... O'Reilly Automotive (ORLY), up 3.9%... Fortinet (FTNT), up 1.5%... Mellanox (MLNX), up 2.9%... ServiceNow (NOW), up just under 1%. ALSO HIGHER: CarMax (KMX), up 1% after announcing a $2B increase to its share repurchase program. DOWN AFTER EARNINGS: Air Methods (AIRM), down 19.8% following preliminary third quarter results... Yelp (YELP), down 13.6%... Core Laboratories (CLB), down 7.9%... Varian Medical (VAR), down 4.9% after reporting fourth quarter results... Open Text (OTEX), down 3.9%... Citrix (CTXS), down 5.7%... Cheesecake Factory (CAKE), down 4.5%... Allied World (AWH), down 4.7%... Lam Research (LRCX), down 3.3%... Skechers (SKX), down just under 1% after reporting third quarter results above analyst estimates... AT&T (T), down 1.5%. ALSO LOWER: DIRECTV (DTV), down just under 1% following AT&T third quarter results... Alcobra (ADHD), down 16% following results of MDX study... WidePoint (WYY), down 8.1% after filing an automatic common stock shelf... New Mountain Finance (NMFC), down 4.4% after filing to sell 5M shares of common stock.
16:21 EDTNOWServiceNow sees FY14 revenues $677M-$679M, consensus $671.6M
16:20 EDTNOWServiceNow sees Q4 revenue $192M-$194M, consensus $191.4M
Subscribe for More Information
16:19 EDTNOWServiceNow reports Q3 EPS 4c, consensus 1c
Subscribe for More Information
15:30 EDTNOWNotable companies reporting after market close
Subscribe for More Information
08:20 EDTETFCE-Trade guidance conservative, says Wells Fargo
Subscribe for More Information
October 21, 2014
16:15 EDTETFCE-Trade reports Q3 DARTs of 153,000, down 1% sequentially
Subscribe for More Information
16:14 EDTETFCE-Trade reports Q3 EPS 29c, consensus 22c
Reports Q3 revenue $440M, consensus $424.93M.
15:30 EDTETFCNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Yahoo! (YHOO), consensus 30c; ACE (ACE), consensus $2.34; Discover Financial (DFS), consensus $1.34; Pinnacle Financial (PNFP), consensus 51c; Broadcom (BRCM), consensus 84c; Intuitive Surgical (ISRG), consensus $3.80; FMC Technologies (FTI), consensus 74c; Robert Half International (RHI), consensus 58c; E-Trade (ETFC), consensus 22c; Nabors Industries (NBR), consensus 36c; Waste Connections (WCN), consensus 54c; Cubist Pharmaceuticals (CBST), consensus 4c; Sonic (SONC), consensus 34c; American Campus Communities (ACC), consensus 43c; Cree (CREE), consensus 36c; Fulton Financial (FULT), consensus 20c; Costamare (CMRE), consensus 41c; Hawaiian Holdings (HA), consensus 78c; Ethan Allen (ETH), consensus 36c; Sabra Health (SBRA), consensus 55c; Rush Enterprises (RUSHA), consensus 51c.
October 20, 2014
08:04 EDTNOWServiceNow should have another beat and raise quarter, says RBC Capital
Subscribe for More Information
07:37 EDTCYTKCytokinetics completes review results from BENEFIT-ALS regarding tirasemtiv
Cytokinetics provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. The company announced that it has completed its review of results from BENEFIT-ALS and has concluded that effects observed on Slow Vital Capacity in patients treated with tirasemtiv are robust and potentially clinically meaningful. In addition, following consultation with clinical and statistical experts, the company believes that data from BENEFIT-ALS support progression of tirasemtiv to a potential Phase III clinical trial in patients with amyotrophic lateral sclerosis (ALS). The company also announced that it has begun regulatory interactions with the U.S. Food and Drug Administration regarding results from BENEFIT-ALS and has received initial feedback from the FDA. The company believes that effects on SVC could be a Phase III clinical trial endpoint and could support registration of tirasemtiv as a potential treatment for patients with ALS. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015. Cytokinetics has received feedback from the FDA following initial communications regarding tirasemtiv and BENEFIT-ALS. The company believes that the FDA may be willing to consider a potential registration path for tirasemtiv relating to effects on SVC. The company expects to have additional interactions with the FDA and other regulatory authorities. In addition, the company has commenced Phase III readiness activities including designing a potential Phase III clinical trial in order to inform plans, timelines and costs associated with the further development of tirasemtiv.
06:33 EDTETFCE-Trade upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
October 14, 2014
09:16 EDTNOWServiceNow initiated with a Positive at OTR Global
Subscribe for More Information
07:59 EDTETFCSchwab, Ameritrade look 'deeply undervalued,' says Deutsche Bank
Subscribe for More Information
October 13, 2014
09:23 EDTNOWHP could buy lower valuation company, says Bernstein
Subscribe for More Information
07:35 EDTCYTKCytokinetics announces development program update for CK-2127107
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use